Effectiveness and safety of 17β-estradiol / drospirenon для менопаузальной гормональной терапии у пациенток с риском развития метаболического синдрома
https://doi.org/10.21518/2079-701X-2016-17-120-123
Abstract
Objective: study of effectiveness and safety of indication of a combination 17β-estradiol/drospirenon in patients with various manifestations of the climacteric syndrome and risk of the metabolic syndrome development.
Materials and methods. Results of two-year therapy of climacteric syndrome by 17β-estradiol/drospirenon drug in 21 patient in post-menopause.
Results. As a result of two-year administration of the 17β-estradiol/drospirenon drug in patients with a risk of metabolic syndrome development a significant reduction of Kuppermann index was observed as well as improvement of the skin and mucous tunic state. No negative effect of the drug on lipid exchange values and homeostasis parameters, arterial pressure value, growth of myomatous nodules and thickness of endometrium.
Conclusions. A combination of 17β-estradiol/drospirenon is effective and safe in therapy of climacteric disturbances and might be a drug of choice for patients with a risk of metabolic syndrome development.
About the Authors
N. V. Seledtsova
Institute of Chemical Biology and Fundamental Medicine of the Siberian Department of RAS, Personalized Medicine Center LLC, Novosibirsk
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
T. V. Ovsyannikova
Institute of Chemical Biology and Fundamental Medicine of the Siberian Department of RAS, Personalized Medicine Center LLC, Novosibirsk
Russian Federation
MD
Russian Federation
MD
References
1. Майчук Е.Ю., Юренева С.В., Митрохина Т.В., Воеводина И.В., Моисеенко С.В., Сапунова Д.А., Кузнецов С.Ю. Развитие атеросклероза и остеопороза у женщин. Проблемы женского здоровья, 2010, 3: 51-55.
2. Чеботникова Т.В., Мельниченко Г.А., Андреева Е.Н. Клинические и метаболические проявления климактерического синдрома (обзор литературы). Проблемы репродукции, 2004, 10(2): 69-76.
3. Genazzani AR, Mannella P, Simoncini T. Drospirenone and its antialdosterone properties. Climacteric, 2007, 10(Suppl 1): 11-18.
4. Palacios S, Foidart JM, Genazzani AR. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas, 2006, 55: 297-307.
5. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. AJH, 2005, 18: 797-804.
6. Прилепская В.Н., Межевитинова Е.А., Сасунова Р.А., Иванова Е.В., Летуновская А.Б., Набиева К.Р. Результаты клинического применения препарата, содержащего дроспиренон, у женщин с тяжелой формой предменструального синдрома. Акушерство и гинекология, 2012, 2: 81-85.
7. Lee BS, Kang BM, Yoon BK, Choi H, Park HM, Kim JG. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: A double-blind, randomized, placebo-controlled, multicenter study. Maturitas, 2007, 57(4): 361-369.
8. Davison SL, Bell RJ, Robinson PJ, Jane F, Leech J, Maruff P, Egan GF, Davis SR. Continuouscombined oral estradiol/drospirenone has no detrimental effect on cognitive performance and improves estrogen deficiency symptoms in early postmenopausal women: a randomized placebocontrolled trial. Menopause, 2013, 20(10): 1020-6. doi: 10.1097/GME.0b013e318287474f.
9. Li M, Wang A, Hu L, Song Z, Zhao Y, Sun Y, Yan L, Li X. Effects of estradiol-drospirenone on menopausal symptoms, lipids and bone turnover in Chinese women. Climacteric, 2015, 18(2): 214-8. doi: 10.3109/13697137.2014.978753.
10. Archer DF. Drospirenone and estradiol: a new option for the postmenopausal woman. Climacteric, 2007, 10(Suppl 1): 3-10.
11. Чижова Г.В., Цветкова Т.П. Клинические аспекты применения препарата Анжелик у женщин с тяжелым климактерическим синдромом в постменопаузе. Клиническая геронтология, 2010, 1-2: 64-68.
12. Schürmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and effi cacy of three dose regimens. Climacteric, 2004, 7(2): 189-196.
13. Paoletti AM, Cagnacci A, Di Carlo C, Orrù MM, Neri M, D’Alterio MN, Melis GB. Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone. A prospective randomized placebo controlled study. Gynecol Endocrinol, 2015, 31(5): 384-7. doi:10.3109/09513590.2014.1003294.
14. Archer DF, Thorneycroft IH, Foegh M, et al. Longterm safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause, 2005, 16(6): 716-727.
15. Rizzo MR, Leo S, Franciscis РD, Colacurci N, Paolisso G. Short-term effects of low-dose estrogen/drospirenone vs low-dose estrogen/ dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome. AGE, 2014, 36: 265-274.
16. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab, 2003, 88(6): 2404-2411.
17. Kaygusuz İ1, Simavli SA, Eser A, Inegöl Gümüş I, Yüksel S, Iltemir Duvan ZC, Kafali H. Effects of oral hormone replacement therapy on mean platelet volume in postmenopausal women. Turk J Med Sci, 2014, 44(6): 980-4.
18. De Franciscis P, Mainini G, Labriola D, Leo S, Santangelo F, Luisi A, Russo C, Cerreto FV, Ambrosio D, Torella M. Low-dose estrogen and drospirenone combination: effects on metabolism and endothelial function in postmenopausal women with metabolic syndrome. Clin Exp Obstet Gynecol, 2013, 40(2): 233-5.
19. Lima SM, Reis BF, Yamada SS, Postigo S, Grande RM, Botogoski SR, Campaner AB, Hueb CK, Galvão MA. Effects of drospirenone/estradiol on steroid receptors and Bcl-2 in the postmenopausal endometriu. Climacteric, 2011, 14(5): 551-7.
20. Gerlinger C. , Gude K, Schmelter T, Schaefers M, Endrikat J. 0.5 vs. 1.0 mg estradiol in combination with drospirenone for the treatment of hot flushes. Climacteric, 2015, 18(4): 512-7. doi: 10.3109/13697137.2015.1036855.
21. Archer DF, Schmelter T, Schaefers, M; Gerlinger C, Gude K. A randomized, double-blind, placebocontrolled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause, 2014, 21(Issue 3): 227-235.
22. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol, 2000, 95(5): 726-31.
Review
For citations:
Seledtsova NV, Ovsyannikova TV. Effectiveness and safety of 17β-estradiol / drospirenon для менопаузальной гормональной терапии у пациенток с риском развития метаболического синдрома. Meditsinskiy sovet = Medical Council. 2016;(17):120-123. (In Russ.) https://doi.org/10.21518/2079-701X-2016-17-120-123
Views:
647
Email this article 